{"id":"NCT01230125","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery","officialTitle":"Study to Assess the Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2011-06","completion":"2011-08","firstPosted":"2010-10-28","resultsPosted":"2020-09-03","lastUpdate":"2020-09-03"},"enrollment":311,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cataract"],"interventions":[{"type":"DRUG","name":"Mapracorat","otherNames":["BOL-303242-X"]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"Mapracorat","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.","primaryOutcome":{"measure":"Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells.","timeFrame":"8 days","effectByArm":[{"arm":"Mapracorat","deltaMin":32,"sd":null},{"arm":"Vehicle","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":207},"commonTop":["Eye pain","Corneal edema"]}}